The use of mesenchymal stem cells derived from bone marrow instead of antibody induction may result in a lower incidence of acute rejection in adults receiving related-donor kidney transplants. John Schieszer reports in today’s Medical Minute that these autologous stem cells may help decrease opportunistic infections in this patient population.